AtheroNova (AHRO) Launches New Web Presence to Highlight Clinical Focus
Published Thursday, January 31, 2013 by Justin Kuepper
AtheroNova Inc. (OTCQB: AHRO) has been quietly developing a breakthrough treatment for atherosclerotic plaque over the past couple years, and the launch of its new website and efforts to build awareness at the Noble Financial Conference mark another turn in the right direction. Investors should watch for interest in this stock to build over the near-term as a result.

The company’s lead compound, AHRO-001, is a treatment for atherosclerotic plaque that may show more promise than existing statin drugs, like Pfizer Inc.’s (NYSE: PFE) and AstraZeneca plc’s (NYSE: AZN) treatment options. Leveraging the power of bile salts, the compound acts as “nature’s detergent” to dissolve plaque within artery walls via a process called delipidization.

AtheroNova Inc. (AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the launch of its new website as of January 18, 2013. The website,, has significantly augmented content and graphics to enhance the user experience moving forward.

"We are launching this new site to allow investors and interested parties to follow the coming developments in the Company as we start the transition from pre-clinical to clinical stage," stated CEO Thomas W. Gardner. "In taking the next step in our web presence, we allow users to sign up to receive corporate communications and allow those interested in our lipid-modulation technology to follow us more closely. We invite everyone to log on and explore the new site to sign up for our news alert system"

AtheroNova commissioned service and technology solutions company Equisolve LLC. to design the website and manage its content.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit

Forward-Looking Statements

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
More AHRO Coverage
AtheroNova, Amgen and More Leveraging Russian Initiatives to Grow Biotech Sector
AtheroNova's AHRO-001 Targets Much More than Cholesterol, Shows New UCLA Study
AtheroNova (AHRO) Announces Promising Preclinical Data Around Atherosclerosis
AtheroNova (AHRO) Commences Clinical Trials Targeting Atherosclerosis
Combining Therapies to Amplify the Effects of Statins
AtheroNova (AHRO) Ships Phase I Drugs to Russian Partner CardioNova
AtheroNova (AHRO) Mentioned by Analyst in Life Sciences Report
Finding the Next Big Blockbuster Drug
AtheroNova Receives Russia’s Approval for Phase I Clinical Trials
It's Time to Re-Think the Clinical Approach to Battle Cholesterol and Atherosclerosis
AtheroNova (AHRO) Sets the Stage for Upcoming Clinical Trials with New Board Member
AtheroNova Names Veteran Cleveland Clinic Researcher to Advisory Board
Analyst Believes AtheroNova Inc. (AHRO) Could See $2.00 per Share
New Ways to Treat Atherosclerosis
AtheroNova (AHRO) Receives Buy Rating and $2.00 Price Target